Here are 1-2 brief analogies for Nuvectis Pharma (NVCT):

• Nuvectis Pharma is like an early-stage Genentech (a Roche company), focused on developing new precision medicines for cancer.
• Nuvectis Pharma is similar to Vertex Pharmaceuticals, applying a precision medicine approach specifically to oncology rather than other diseases.

• NXP800: A novel heat shock factor 1 pathway inhibitor under development for the treatment of various cancers.
• NXP900: A small molecule drug candidate designed to inhibit the Proto-oncogene c-Src and YES1 kinases.

Nuvectis Pharma, Inc. (NVCT) is a biopharmaceutical company focused on the development of novel precision medicines for oncology. As a company primarily engaged in research and development, particularly for drug candidates (NXP800 and NXP900) that are still in various stages of clinical development, it does not currently have commercialized products that are sold to major customers.

Therefore, Nuvectis Pharma does not have major customers in the traditional sense, as it has not yet brought any products to market for sale to individuals, hospitals, or other pharmaceutical companies.

Ron Bentsur

Chairman, Chief Executive Officer and President

Ron Bentsur co-founded Nuvectis Pharma in 2020. He has over 20 years of senior leadership experience in the biotechnology industry. Prior to Nuvectis, he served as CEO of UroGen Pharma, Inc. from 2015 to 2019, and as CEO of Keryx Biopharmaceuticals, Inc. from 2009 until 2015, which was acquired by Akebia Therapeutics. As CEO at UroGen and Keryx, he led the clinical development, regulatory approvals, and commercial infrastructure buildouts for the U.S. commercial launches of Jelmyto and Auryxia, respectively. Mr. Bentsur also served as CEO of XTL Biopharmaceuticals, Inc. from 2006 until 2009 and as Investor Relations and CFO of Keryx from 2000 to 2006. He was a Board Director at Stemline Therapeutics, Inc. from 2009 until its acquisition by the Menarini Group in June 2020.

Michael Carson

Vice President of Finance

Michael Carson joined Nuvectis Pharma as Vice President of Finance and Corporate Secretary in March 2022. He has over 20 years of experience in corporate finance, accounting, and operations within the biopharma and medical device sectors. His previous roles include Vice President of Finance at XyloCor Therapeutics, Inc., Global Controller (consultant) at Smiths Medical (a division of Smiths Group), and Director of FP&A at Neuronetics (NASDAQ: STIM).

Enrique Poradosu, PhD

Executive Vice President, Chief Scientific and Business Officer

Dr. Enrique Poradosu co-founded and has served as the Chief Scientific and Business Officer of Nuvectis since 2020. Prior to that, he served as VP Business and Scientific Strategy at Keryx Biopharmaceuticals, Inc. (acquired by Akebia Therapeutics) from 2003 until 2016.

Shay Shemesh

Executive Vice President, Chief Development and Operations Officer

Shay Shemesh co-founded and has served as the Chief Development and Operations Officer of Nuvectis Pharma since 2020. From 2015 until 2020, he served as Senior Vice President, Clinical and Regulatory Affairs at Stemline Therapeutics, Inc.

The key risks for Nuvectis Pharma (NVCT) are primarily associated with the inherent challenges of biopharmaceutical development, particularly its reliance on successful clinical trials and ongoing funding for its limited pipeline.

1. Clinical Trial Failure and Regulatory Approval: Nuvectis Pharma's business is heavily dependent on the successful development and regulatory approval of its drug candidates. The recent termination of the NXP800 development program for platinum-resistant, ARID1a-mutated ovarian cancer, despite some biological activity in a Phase 1b study, underscores the significant risk of clinical trial failures. While NXP800 is being evaluated for other indications like endometrial and prostate cancers, and NXP900 is progressing to Phase 1b studies for advanced solid tumors and non-small cell lung cancer, the overall success rate for drugs transitioning from Phase 1 to market approval in the biotech industry is low, around 20%. Failure to achieve positive clinical outcomes or secure regulatory approvals for its drug candidates would severely impact the company's viability.
2. Funding and Capital Needs: As an early-stage biopharmaceutical company with no revenue, Nuvectis Pharma incurs significant research and development expenses and operates at a net loss. While a recent funding round in February 2025 provided approximately $39 million in cash, extending its cash runway into the second half of 2027, drug development is a capital-intensive process that will require substantial additional funding to bring its candidates to commercialization. The ability to secure future financing will largely depend on positive clinical data from its ongoing trials.
3. Dependence on a Limited Clinical Pipeline: With the discontinuation of NXP800 in its primary indication, Nuvectis Pharma's near-term focus heavily shifts to NXP900 as its lead drug candidate. This concentration on a limited number of early-stage assets increases the company's risk profile. The success or failure of NXP900's clinical outcomes will be a critical determinant of the company's future trajectory, as the pipeline is still considered to be in early stages.

Nuvectis Pharma (NASDAQ: NVCT) focuses on developing precision medicines for oncology, with two main product candidates, NXP800 and NXP900, targeting significant addressable markets.

NXP800

NXP800, a novel heat shock factor 1 pathway inhibitor, is being developed for the treatment of various cancers, with a particular focus on platinum-resistant ovarian cancer. The estimated addressable market size for platinum-resistant ovarian cancer is approximately $4 billion. Additionally, NXP800 is being evaluated for its potential in advanced prostate cancer and bile duct cancers. Nuvectis Pharma's NXP800 specifically targets ARID1a-mutated ovarian cancer.

NXP900

NXP900 is a small molecule drug candidate designed to inhibit the Proto-oncogene c-Src and YES1 kinases. This product targets SRC/YES1-driven tumors, with over 50,000 new cases annually in the U.S. in areas such as lung cancer, head and neck cancers, and other solid tumors. The global market for non-small cell lung cancer (NSCLC), one of the indications NXP900 is targeting, is valued at well over $10 billion per year. Lucid Capital Markets projects peak non-risk-adjusted sales for NXP900 to exceed $900 million across multiple cancer indications by 2041. The product is also being advanced for potential use in kidney cancer, mesothelioma, head and neck squamous cell carcinoma (HNSCC), bladder cancer, and esophageal cancer.

1. Successful Clinical Development and Potential Commercialization of NXP900: The progression of NXP900 through its Phase 1b clinical trials is a critical revenue driver. This includes its evaluation as a single agent for advanced solid tumors with specific genetic alterations, and in combination with EGFR and ALK inhibitors for non-small cell lung cancer (NSCLC) patients who have developed resistance to these treatments. Nuvectis anticipates multiple clinical data readouts for NXP900 in 2026, which are crucial milestones for its future market entry and revenue generation.
2. Expansion of NXP900 into New Oncology Indications and Geographical Markets: Nuvectis's strategy involves exploring NXP900 in a broad range of genetically-defined solid tumors. Furthermore, analyst commentary indicates plans for expansion beyond the U.S.. Successful trials and subsequent approvals in additional cancer types and new regions would significantly broaden the addressable market and contribute to future revenue growth.
3. Strategic Re-evaluation and Potential Development of NXP800 in Alternative Cancer Types: While the development of NXP800 for ovarian cancer was halted, Nuvectis has stated its intention to evaluate its potential in other indications, such as endometrial and prostate cancers. Should these evaluations yield positive results and lead to the initiation of new clinical programs, NXP800 could emerge as an additional, albeit longer-term, driver of revenue within the 2-3 year timeframe, as it progresses through early clinical stages for new indications.

Share Issuance

• In February 2025, Nuvectis Pharma completed an underwritten public offering, generating approximately $15.5 million in gross proceeds from the sale of 3,105,000 shares of common stock at $5.00 per share.
• In May 2025, the company established a new "At the Market" (ATM) offering program allowing the sale of up to $60 million in common stock through Leerink Partners. This program replaced a previous $40 million ATM program, under which $18.6 million in shares had been sold.
• In July 2022, Nuvectis Pharma conducted a private placement, issuing 1,924,689 shares of common stock (or pre-funded warrants) at $8.25 per share, resulting in gross proceeds of approximately $15.9 million.

Inbound Investments

• In July 2022, Nuvectis Pharma received approximately $15.9 million in gross proceeds through a private placement from healthcare-focused institutional and accredited investors.
• In August 2021, the company closed a $15 million Series A preferred stock financing round with institutional and private investors.

Capital Expenditures

• Proceeds from the February 2025 public offering were earmarked to advance development programs for NXP800 and NXP900, hire additional personnel, cover capital expenditures, and fund general corporate purposes.